Poster abstracts
Poster number 48 submitted by Hongran Yin
Gastric cancer therapy by system injection of RNA nanoparticles carrying both ligand and siRNA
Daxaing Cui, Chunlin Zhang, Bing Liu, Tong Du, Kan Wang, Yanlei Liu (Institute of Nano Biomedicine and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of the Ministry of Education, Dept. Instrument Science and Engineering, Bio-X center), Chao Li, Fei Pan, Yuming Yang, Jian Ni, (Institute of Nano Biomedicine and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of the Ministry of Education, Dept. Instrument Science and Engineering, Bio-X center), Yi Shu (Nanobiotechnology Center, Markey Cancer Center, and Dept. Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA. ), Dan Shu, Hui Li, Hongran Yin (College of Pharmacy; College of Medicine/Dept. Physiology Cell Biology/Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, 43210, USA.), Peixuan Guo (College of Pharmacy; College of Medicine/Dept. Physiology Cell Biology/Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, 43210, USA.), Brand-Saberi (Dept. Anatomy & Mol. Embryology, Ruhr-University of Bochum, 44780 Bochum, Germany. )
Abstract:
Gastric cancer therapy by system injection of RNA nanoparticles carrying both ligand and siRNA
Daxiang Cui, Chunlei Zhang, Bing Liu, Yi Shu, Tong Du, Dan Shu, Kan Wang, Fangping Dai, Yanlei Liu, Chao Li, Fei Pan, Yuming Yang, Jian Ni, Hui Li, Beate Brand-Saberi, Hongran Yin, Peixuan Guo*
Gastric cancer is one of the leading causes of cancer-related death worldwide and is difficult to treat. Recently, RNA nanotechnology has emerged as an important and novel platform due to its tremendous versatility, high thermodynamic stability, less toxicity and favorable in vivo attributes. Using RNA nanotechnology to construct nanoparticles, exosomes and micelles have become a promising method for cancer therapy. Here we report the use of the three-way junction (3WJ) of the bacteriophage phi29 motor pRNA as a scaffold to incorporate targeting ligands, a NIR imaging marker and siRNA for gene silencing and regression of gastric cancer tumors in animal models. In vitro assay revealed that the folate incorporated RNA nanoparticles specifically bound to gastric cancer cells, knocked down oncogenic genes and was able to induce gastric cancer cell apoptosis. Animal trials confirmed that these RNA nanoparticles could be used to target gastric tumors in vivo, while showing little accumulation in other vital organs and tissues. Furthermore, the volume of gastric tumors noticeably decreased during the course of the treatment. The results indicate that this novel RNA nanotechnology can overcome conventional cancer therapeutics to stomach cancer without damaging normal cells and tissues and improve the therapeutic effects.
References:
1. Guo P. 2010. The emerging field of RNA nanotechnology. Nature Nanotechnology. 5, 833
2. Cui D .Guo P. 2015. Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA. Sci Rep. 5:10726.
3. Shu D .Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nature Nanotechnology. 2011; 6:658-67.
Keywords: Gastric Cancer, RNA nanotechonogy, siRNA